XNCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Xencor Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$23.19+0.34 (+1.49%)
Close on Oct 19, 2026
- Market cap
- $1.76B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$8.42 (+57.01%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Xencor Inc saw revenue fall 28.6% to $104.97M over the twelve months to Jun 30, 2026. Free cash flow was -$208.29M.
Revenue
$104.97M
-28.6% vs. a year earlier
Operating income
-$216.08M
TTM Q2 2026
Free cash flow
-$208.29M
TTM Q2 2026
EPS, diluted
-$2.17
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.76B
- P/E ratio
- –
- Price to sales
- 16.76
- Price to book
- 3.50
- Dividend yield
- –
- Free cash flow yield
- -11.84%
Fundamentals
- Revenue
- $104.97M
- Net income
- -$163.33M
- EPS, diluted
- -$2.17
- Free cash flow
- -$208.29M
- Book value per share
- $6.63
- Diluted shares
- 76M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$104.97M-28.6% YoY
Operating income
-$216.08M
Net income
-$163.33M
EPS, diluted
-$2.17
Free cash flow
-$208.29M
Reported periodTrailing twelve months